You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Bacteriophage therapy
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Last revisionBoth sides next revision
home:othertreatments:bacteriophage_therapy [01.03.2012] – external edit 127.0.0.1home:othertreatments:bacteriophage_therapy [09.16.2017] – [Bacteriophage therapy] sallieq
Line 6: Line 6:
 There is no evidence to suggest that the introduction of additional organisms with their DNA and RNA could have any long-term benefit.  There is no evidence to suggest that the introduction of additional organisms with their DNA and RNA could have any long-term benefit. 
  
-In fact, the [[home:pathogenesis:horizontal_gene|horizontal gene transfer]] of DNA and RNA between organisms represents the primary mechanism by which the microbiota causing Th1 disease accumulates its pathogenic capability. Adding new pathogens only increases statistical risk: the practice might reduce overall pathogenicity or it might increase it. +Indeed, the [[home:pathogenesis:horizontal_gene|horizontal gene transfer]] of DNA and RNA between organisms represents the primary mechanism by which the microbiota causing Th1 disease accumulates its pathogenic capability. Adding new pathogens only increases statistical risk: the practice might reduce overall pathogenicity or it might increase it. 
  
 Some patients do experience improvement of symptoms during an acute infection, but not cure. In the long run, the extra pathogens can only present more problems. Some patients do experience improvement of symptoms during an acute infection, but not cure. In the long run, the extra pathogens can only present more problems.
home/othertreatments/bacteriophage_therapy.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.